(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Curcumin + doxorubicin)’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Curcumin + doxorubicin) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Curcumin + doxorubicin) overview

Curcumin in combination with doxorubicin is under development for the treatment of chemo-resistant colon cancer, prostate cancer, esophageal  cancer, nasopharyngeal  cancer, soft tissue sarcoma, leiomyosarcoma, cholangiocarcinoma, carcinosarcoma, poorly differentiated sarcoma, triple negative breast cancer, ovarian, pancreatic cancers, malignant glioma, glioblastoma multiforme, multiple myeloma, colorectal cancer and solid tumor. It is a nanoparticle. Imx-110 is a first-in-class combination therapeutic candidate, that contains curcumin combined with a small amount of doxorubicin, encased in a nano-sized delivery system for optimal tumor penetration. Doxorubicin acts by targeting DNA and curcumin targets NF-kB/Stat3/pan-tyrosine kinase. The drug candidate is developed based on TME normalization technology.

Immix BioPharma overview

Immix BioPharma is a biopharmaceutical company focused on developing novel cancer therapies to combat resistant tumors. Its products portfolio includes Imx-109, a small-molecule agent used for the treatment of solid tumors; Imx-110, a nanoparticle delivery vehicle coloaded with small doses of cytotoxin and cytotoxic agents such as doxorubicin, paclitaxel, carboplatin, PD1 inhibitors, T Cell therapies for triple-negative breast cancer, ovarian cancer, colon cancer, and malignant glioma preclinical models. Immix BioPharma is developing therapy platform in the field of nanotechnology and drug delivery for the treatment of cancers. The company works in collaboration with other research institutes and universities for research and development of its cancer therapies. Immix BioPharma is headquartered in Los Angeles, California, the US.

Quick View (Curcumin + doxorubicin) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Curcumin + doxorubicin)
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.